EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Euromedis Groupe SA (ALEMG) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Euromedis Groupe SA €5.32, price €5.20, upside +2.3%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · FR · ISIN FR0000075343

EG Some data Sep 23, 2026

Euromedis Groupe SA

ALEMG · PA

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value €5.32 · Fairly valued (+2%)
!Quality 64/100
!Weak Growth (revenue 5y −26.7 %/yr)
!Loss-making · -0.3% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (4/13)
!Narrow moat 19/100
!Insider activity 30/100
!Evidence only medium, so the estimate is less certain
Watch Euromedis Groupe SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€16.50 €3.45 Fair Value €5.32 Aug 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €3.45 – €16.50 · fair‑value band €4.20 – €5.93 · the €5.20 price screens below the €5.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Euromedis Groupe in your weekly email

Every Wednesday you see whether Euromedis Groupe is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Laboratoires Euromedis manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities.

Show more

Laboratoires Euromedis manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, microperfusionists; infusion and transfusion services, catheters, accessories, waste collectors; disinfection, hygiene, and surface protection; panty liners and sanitary napkins, changes, absorbent underwear, support briefs, and bed pad; rollators, cannes, and transfer products; bed tables, reclining chairs, and bath and toilet products; blood pressure monitors, thermometers, pulse oximeters, and other diagnostic products; urine bags, probes, and drains; and oxygen therapy products. The company was founded in 1985 and is based in Mouy, France.

Stock analysis

Euromedis Groupe SA (ALEMG) currently trades at €5.20, while our model-based Fair Value estimate is €5.32, implying the stock looks roughly 2.3% fairly valued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €5.48 per share, and 2 of the 6 models we run sit above the €5.20 price.

Bear case: the Asset-Based group reads lowest at €3.86, and 4 of the 6 models stay below the price. Evidence for this calculation is medium.

Scenario range: €4.20 (bear) to €5.93 (bull), the price of €5.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Euromedis Groupe SA reported revenue of €40.8M in FY2025 versus €112M in FY2021, a compound −22.3%/yr. Reported net income was −€100K in FY2025.

Key figures

Market cap €14.9M · P/E ratio 13.9 · P/S ratio 0.34 · EPS (TTM) €−0.0500 · Net margin −0.2% · Return on equity −0.8% · Return on assets (EBIT) −3.0% · Operating margin 1.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 36% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 2%, ALEMG screens richer than that median.

Fair Value models

Bear €4.20 Fair Value €5.32 Bull €5.93
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV €4.18 €4.25 €4.32 74
ROIC Compounder €4.18 €4.25 €4.32 72
EV/EBITDA €8.93 €10.67 €12.41 67
All 6 models by family
Earnings-Based
EPV €4.18 €4.25 €4.32 74
Multiples
EV/EBIT €5.04 €5.48 €5.93 66
EV/EBITDA €8.93 €10.67 €12.41 67
EV/Revenue €4.66 €5.06 €5.47 54
Asset-Based
NCAV (Graham) €2.88 €3.86 €5.76 54
Economic Profit
ROIC Compounder €4.18 €4.25 €4.32 72

Open the full fair value analysis →

Notify me when ALEMG reaches fair value

Put ALEMG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 64 · Market factors (momentum, volatility) 62

Profitability 35
Margins and returns on capital today
Quality Growth 92
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 74
Calm price path (market factor)
Momentum 52
Price trend over the last 3–12 months (market factor)
52W Momentum 66
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+12.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.7%
Start year 2020 (pandemic). Over 10 years: −5.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.8% (2020) → 0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ALEMG, get fair value alerts →

Compare Euromedis Groupe SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside +3% · Below median
Profitability
Return on assets 1% · Bottom 25%
Net margin (TTM) 0% · Bottom 25%
Operating margin (TTM) 2% · Below median
Growth and dividend
Revenue growth 14% · Top 25%
Balance sheet
Debt / equity 0.37× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 13.9× · Cheaper than median
P/B 1.02× · Pricier than median
P/S (TTM) 0.41× · Pricier than median
EV/EBITDA 11.8× · Pricier than median
PEG 0.44× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)36 · sector 42
FUTURE (revenue growth)68 · sector 17
PAST (return on equity)0 · sector 27
HEALTH (low debt)81 · sector 96
DIVIDEND (yield)0 · sector 59

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $880.50 $819.31 −7%
Cencora, Inc COR $312.28 $211.07 −32%
Cardinal Health, Inc CAH $221.27 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.06 ¥42.67 +166%
Sinopharm Group 1099 HK$15.06 HK$58.89 +291%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.67 ¥26.64 +35%
Jointown Pharmaceutical Group 600998 ¥4.89 ¥9.84 +101%
China National Medicines Corporation 600511 ¥26.11 ¥58.47 +124%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Euromedis Groupe SA · Fair Value
€5.32 +2%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Euromedis Groupe SA Fair Value". https://www.fairvalue-calculator.com/stock/ALEMG

Frequently asked questions

Is Euromedis Groupe SA (ALEMG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €5.32 versus a price of €5.20, about +2% upside (fairly valued).
What is the fair value of ALEMG?
Our model-based fair value for Euromedis Groupe SA is €5.32 (as of Sep 23, 2026), built from audited fundamentals. The current price: €5.20.
What is the quality score of ALEMG?
Euromedis Groupe SA has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Euromedis Groupe SA (ALEMG)?
Our model-based price target is the fair value of €5.32 (as of Sep 23, 2026) from 6 valuation models. Cautious scenario €4.20, optimistic scenario €5.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Euromedis Groupe SA stock forecast for 2026?
Our models put fair value at €5.32, about +2% upside versus a price of €5.20 (fairly valued). Cautious scenario €4.20, optimistic scenario €5.93. The calculation is refreshed regularly with new filings.
What is the revenue of Euromedis Groupe SA (ALEMG)?
Euromedis Groupe SA reported trailing-twelve-month revenue of about €41.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Euromedis Groupe SA (ALEMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Euromedis Groupe SA it is €5.32 per share (as of Sep 23, 2026), against a price of €5.20. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Euromedis Groupe SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALEMG trades below its calculated fair value: price €5.20, fair value €5.32, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALEMG?
No. The price is what the market pays today (€5.20); the fair value is what the company's own numbers justify (€5.32). For Euromedis Groupe SA the two are €0.1200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Euromedis Groupe SA worth?
The market values Euromedis Groupe SA at about €14.9M (market capitalisation, as of Sep 23, 2026). Per share that is €5.20; our models calculate a fair value of €5.32 per share.
What do the bullish and bearish scenarios say about ALEMG?
Our models span a range for Euromedis Groupe SA: cautious scenario €4.20, base €5.32, optimistic €5.93 per share (as of Sep 23, 2026, price €5.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALEMG?
Euromedis Groupe SA trades at a price-to-earnings ratio of 13.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €5.32 is built from several models across several years. Other multiples: PEG 0.4, P/B 1.0, P/S 0.4, EV/EBITDA 11.8.
What is the PEG ratio of ALEMG?
The PEG ratio of Euromedis Groupe SA is 0.44 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Euromedis Groupe SA (ALEMG)?
Balance-sheet figures for Euromedis Groupe SA (as of Sep 23, 2026): return on equity −0.8%, debt of 0.37 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is ALEMG from its 52-week high?
Euromedis Groupe SA trades at €5.20, about 10% below its 52-week high of €5.75 and 36% above the low of €3.83 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €5.32 is for.
Which stocks are comparable to Euromedis Groupe SA?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Euromedis Groupe SA stock attractive at the current price?
The data as of Sep 23, 2026: price €5.20, calculated fair value €5.32 (+2%), Quality Score 64/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALEMG calculated?
We run Euromedis Groupe SA through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €5.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Euromedis Groupe SA currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Euromedis Groupe SA (ALEMG)?
The closing price on Sep 24, 2026 was €5.20. Our model-based fair value is €5.32, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Euromedis Groupe SA right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Euromedis Groupe SA

How large is the market capitalisation of Euromedis Groupe SA (ALEMG)?
The market capitalisation of Euromedis Groupe SA is €14.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Euromedis Groupe SA (ALEMG)?
The price-to-sales ratio of Euromedis Groupe SA is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Euromedis Groupe SA (ALEMG)?
Earnings per share at Euromedis Groupe SA are €−0.0500 (price ÷ EPS = P/E 13.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Euromedis Groupe SA (ALEMG)?
The net margin of Euromedis Groupe SA is −0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Euromedis Groupe SA (ALEMG)?
The return on equity (ROE) of Euromedis Groupe SA is −0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Euromedis Groupe SA (ALEMG)?
On an EBIT basis the return on assets of Euromedis Groupe SA is −3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Euromedis Groupe SA (ALEMG)?
The operating margin of Euromedis Groupe SA is 1.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Euromedis Groupe SA (ALEMG)?
Revenue at Euromedis Groupe SA is growing +13.6% versus a year earlier (3y avg −9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Euromedis Groupe SA (ALEMG)?
Earnings per share at Euromedis Groupe SA are growing +329% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Euromedis Groupe SA (ALEMG) generate?
The free cash flow of Euromedis Groupe SA is −€2.1M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Euromedis Groupe SA (ALEMG) hold?
Euromedis Groupe SA holds more cash than debt, €10.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Euromedis Groupe SA in the live analysis

One click puts Euromedis Groupe SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.